Roche Holding AG’s Genentech unit achieved superior phase III results with its KRAS G12C inhibitor divarasib over approved therapies in previously treated non-small-cell lung (NSCLC) cancer patients.

Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio ...

Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical ...

Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and 2023’s $10.75 billion over the same period and trailing 2025’s $17.56 billion.

(HSCT) following U.S. FDA approval of Tregzi, a first-of-its-kind, personalized cell therapy. Previously known as Orca-T, Tregzi is indicated for use in matched-donor HSCT with myeloablative ...

MED-EL Elektromedizinische Geräte GmbH has acquired two gene therapy programs from Rescue Hearing Inc. for genetic hearing and balance disorders.

Nearly 60% of venture capital financing rounds in the first half (H1) of 2026 were over $100 million, with the volume of ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Candela, Cerenome, Eli Lilly, Innovent, Kyowa, Orion, Pacira, Plus, Shilpa, Zimmer.

Ipsen SA announced its second acquisition of the week, saying it will pay €700 million (US$797 million) for Memo Therapeutics ...

The House Select Committee on China launched an investigation into clinical trials involving U.S. companies that are ...

Researchers at East China Normal University and collaborators reported the discovery and optimization of a series of SUCNR1 antagonists for cancer immunotherapy.

Pacific, including data readouts and publications: Hutchmed, Otsuka.